RATIONALE-306 previously demonstrated improved overall survival (OS) in participants treated with tislelizumab plus chemotherapy versus those receiving placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma, with a minimum follow-up of approximately 15 months. Explo...
H. Yoon, Ken Kato, E. Raymond et al.· Nature Communications· 0 citations
BACKGROUND
Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....
K. Kato, J. Ajani, Y. Doki et al.· Annals of Oncology· 2 citations
Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...
S. Rha, L. Wyrwicz, P. Yanez et al.· ESMO Open· 1 citation· ⚡1
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.